Skip to main content
    G

    GeneDx Holdings Corp. (WGS)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $51.02
    -1.35 (-2.58%)

    Market Cap: $1.57B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    GeneDx Holdings Corp. (WGS) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect GeneDx Holdings (WGS) to earn $0.11 per share in the fiscal year ending Dec 31, 2026, on revenue of $478.02M. Of 8 analysts, 8 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 3 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 8 ratings average 1.88, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.

    RatingAnalystsShare
    Strong Buy112.5%
    Buy787.5%
    Hold00.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    8

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus rises 972.7% and revenue estimates rise 21.9%.

    Fiscal year ending Dec 31, 2026
    $0.11
    EPS consensus, revenue $478.02M
    Fiscal year ending Dec 31, 2027
    $1.18
    EPS consensus, revenue $582.90M
    Next report
    Feb 22, 2027
    Confirmed, after the close

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$0.11$0.02 to $0.224$478.02M$474.90M to $483.40M9
    Dec 31, 2027$1.18$0.44 to $2.005$582.90M$543.70M to $611.00M8

    Quarterly Estimates

    The EPS consensus falls from $0.41 for the quarter ending Dec 31, 2026 to -$0.01 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$0.41$0.37 to $0.539$137.43M$130.14M to $149.52M9
    Mar 31, 2027-$0.01-$0.16 to $0.103$122.87M$115.30M to $130.70M6

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 10 upward and 7 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202632
    Fiscal year ending Dec 31, 202753
    Quarter ending Mar 31, 202722

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 15.4% from $0.13.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$0.11$0.13$0.13$0.13$0.13-15.7%
    Fiscal year ending Dec 31, 2027$1.18$1.20$1.20$1.17$1.17+1.0%
    Quarter ending Mar 31, 2027-$0.01$0.04$0.04$0.06$0.06N/A

    Frequently Asked Questions About WGS

    What is the WGS stock forecast?

    Consensus analyst estimates put GeneDx Holdings's EPS at $0.11 for the fiscal year ending Dec 31, 2026, on revenue of $478.02M. The consensus rating from 8 analysts is Buy.

    How do analysts rate WGS stock?

    Of 8 analysts covering GeneDx Holdings, 1 rates it Strong Buy, 7 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from WGS next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.11, with estimates from $0.02 to $0.22 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $1.18, with estimates from $0.44 to $2.00 from 5 analysts.

    What revenue do analysts expect from GeneDx Holdings next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $478.02M, with estimates from $474.90M to $483.40M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $582.90M, with estimates from $543.70M to $611.00M.

    How many analysts cover WGS?

    8 analysts rate GeneDx Holdings stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.